Glasdegib with intensive/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high-risk myelodysplastic syndromes.

Cancer Sci · 2024 · PMC11006982 · PMID 38327103

Europe PMC DOI

hedged sentence

0.1100

closest p · 2.2× alpha

0.1100

boldest claim

The sentences

failed to reach statistical significancep = 0.11not close (p > 0.1)

15 , 31 , 32 In the global phase III VIALE‐C trial, the addition of venetoclax to LDAC in patients ineligible for intensive chemotherapy improved the median OS from 4.1 months to 7.2 months, but the difference failed to reach statistical significance ( p = 0.11). 32 The CR/CRi rate was significantly improved from 13% with LDAC to 48% with venetoclax plus LDAC ( p < 0.001).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.